Inflammation from ADT may cause fatigue in prostate cancer patients

Vaccination campaign picks up speed around the world
4 January 2021
No decision on Moderna vaccine on Monday: EU regulator
4 January 2021

Inflammation from ADT may cause fatigue in prostate cancer patients

Prostate cancer is one of the most common cancers among men in the U.S. For many patients, hormone therapy is a treatment option. This type of therapy, also called androgen deprivation therapy (ADT), reduces the level of testosterone and other androgens in the body. Lowering androgen levels can make prostate cancer cells grow more slowly or shrink tumors over time. However, patients receiving ADT often experience higher levels of fatigue, depression and cognitive impairment.

Comments are closed.